<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        299-325-19
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ESOMA 40 MG DELAYED RELEASE CAPSULES
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ESOMEPRAZOLE MAGNESIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Delayed-release tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        40.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="RIYADH PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 407]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A02BC05
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>ESOMA contains a medicine called esomeprazole. This belongs to a group of medicines called &lsquo;proton pump inhibitors&rsquo;. They work by reducing the amount of acid that your stomach produces.</p><p>ESOMA is used to treat the following conditions:</p><p><u>Adults</u></p><ul><li>&lsquo;Gastro-oesophageal reflux disease&rsquo; (GORD). This is where acid from the stomach escapes into the oesophagus (the tube which connects your throat to your stomach) causing pain, inflammation and heartburn.</li><li>Ulcers in the stomach or upper part of the gut (intestine) that are infected with bacteria called &lsquo;<em>Helicobacter pylori</em>&rsquo;. If you have this condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer to heal.</li><li>Stomach ulcers caused by medicines called NSAIDs (Non-Steroidal Anti-Inflammatory Drugs). ESOMA can also be used to stop stomach ulcers from forming if you are taking NSAIDs.</li><li>Too much acid in the stomach caused by a growth in the pancreas (Zollinger-Ellison syndrome).</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Prolonged treatment after prevention of rebleeding of ulcers with intravenous esomeprazole.</p><p><u>Adolescents aged 12 years and above</u></p><ul><li>&lsquo;Gastroesophageal reflux disease&rsquo; (GORD). This is where acid from the stomach &nbsp;escapes into the esophagus (the tube which connects your throat to your stomach) causing pain, inflammation and heartburn.</li><li>Ulcers in the stomach or upper part of the gut (intestine) that are infected with bacteria called &lsquo;<em>Helicobacter pylori</em>&rsquo;. If you have this condition, your doctor may also prescribe antibiotics to treat the infection and allow the ulcer to heal.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take ESOMA:</strong></p><ul><li>If you are allergic to esomeprazole or any of the other ingredients of this medicine (listed in Section 6).</li><li>If you are allergic to other proton pump inhibitor medicines (e.g. pantoprazole, lansoprazole, &nbsp;rabeprazole, omeprazole).</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking a medicine containing nelfinavir (used to treat HIV infection).</p><p>Do not take ESOMA if any of the above apply&nbsp;to you. If you are not sure, talk to your doctor or pharmacist before taking ESOMA.</p><p><strong>Warnings and precautions:</strong></p><p>Talk to your doctor or pharmacist before taking ESOMA:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe liver problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe kidney problems.</p><ul><li>If you have ever had a skin reaction after treatment with a medicine similar to ESOMA that reduces stomach acid.</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are due to have a specific blood test (Chromogranin A).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have vitamin B12 deficiency</p><p>ESOMA may hide the symptoms of other diseases.&nbsp;<strong>Therefore, if any of the following happen to you before you start taking ESOMA or while you are taking it, talk to your doctor straight away:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You lose a lot of weight for no reason and have problems swallowing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You get stomach pain or indigestion.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You begin to vomit food or blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You pass black stools (blood-stained faeces).</p><p>If you have been prescribed ESOMA &ldquo;on demand&rdquo; you should contact your doctor if your symptoms continue or change in character.</p><p>Taking a proton pump inhibitor like ESOMA, especially over a period of more than one year, may slightly increase your risk of fracture in the hip, wrist or spine. Tell your doctor if you have osteoporosis or if you are taking corticosteroids (which can increase the risk of osteoporosis).</p><p>If you get a rash on your skin, especially in areas exposed to the sun tell your doctor as soon as you can, as you may need to stop your treatment with ESOMA. Remember to also mention any other ill-effects like pain in your joints.</p><p><strong>Other medicines and ESOMA </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes medicines that you buy without a prescription. This is because ESOMA can affect the way some medicines work and some medicines can have an effect on ESOMA.</p><p>Do not take ESOMA Capsules if you are taking a medicine containing nelfinavir (used to treat HIV infection).</p><p>Tell your doctor or pharmacist if you are taking any of the following medicines:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atazanavir (used to treat HIV infection).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clopidogrel (used to prevent blood clots).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ketoconazole, itraconazole or voriconazole (used to treat infections caused by a fungus).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Erlotinib (used to treat cancer).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Citalopram, imipramine or clomipramine (used to treat depression).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diazepam (used to treat anxiety, relax muscles or in epilepsy).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Phenytoin (used in epilepsy). If you are taking phenytoin, your doctor will need to monitor you when you start or stop taking ESOMA.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines that are used to thin your blood, such as warfarin. Your doctor may need to monitor you when you start or stop taking ESOMA.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cilostazol (used to treat intermittent claudication &ndash; a pain in your legs when you walk which is caused by an insufficient blood supply).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cisapride (used for indigestion and heartburn).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Digoxin (used for heart problems).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methotrexate (a chemotherapy medicine used in high doses to treat cancer) &ndash; if you are taking a high dose of methotrexate, your doctor may temporarily stop your ESOMA treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tacrolimus (organ transplantation).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rifampicin (used for treatment of tuberculosis).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St. John&rsquo;s wort (<em>Hypericum perforatum)</em>&nbsp;(used to treat depression).</p><p>If your doctor has prescribed the antibiotics amoxicillin and clarithromycin as well as ESOMA to treat ulcers caused by&nbsp;<em>Helicobacter pylori</em>&nbsp;infection, it is very important that you tell your doctor about any other medicines you are taking.</p><p><strong>ESOMA with food and drink</strong></p><p>You can take your capsules with food or on an empty stomach.</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p>If you are pregnant, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Your doctor will decide whether you can take ESOMA during this time. It is not known if ESOMA passes into breast milk. Therefore, you should not take ESOMA if you are breastfeeding.</p><p><strong>Driving and using machines</strong></p><p>ESOMA is not likely to affect you being able to drive or use any tools or machines. However, side effects such as dizziness and blurred vision may uncommonly or rarely occur (see section 4). If affected, you should not drive or use machines.</p><p><strong>Important Information</strong></p><p><strong>ESOMA contains sucrose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, talk to your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are taking this medicine for a long time, your doctor will want to monitor you (particularly if you are taking it for more than a year).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor has told you to take this medicine as and when you need it, tell your doctor if your symptoms change.</p><p><strong>How much to take</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will tell you how many capsules to take and how long to take them for. This will depend on your condition, how old you are and how well your liver works.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended doses are given below.</p><p><strong><u>Adults aged 18 and above</u></strong></p><p><strong>To treat heartburn caused by gastro-oesophageal reflux disease (GORD):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor has found that your food pipe (esophagus) has been slightly damaged, the recommended dose is one ESOMA 40 mg capsule once a day for 4 weeks. Your doctor may tell you to take the same dose for a further 4 weeks if your esophagus has not yet healed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose once the esophagus has healed is one ESOMA 20 mg &nbsp;capsule once a day</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your esophagus has not been damaged, the recommended dose is one ESOMA 20 mg &nbsp;capsule each day. Once the condition has been controlled, your doctor may tell you to take your medicine as and when you need it, up to a maximum of one ESOMA 20 mg &nbsp;capsule each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe liver problems, your doctor may give you a lower dose.</p><p><strong>To treat ulcers caused by&nbsp;<em>Helicobacter pylori</em>&nbsp;infection and to stop them coming back:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is one ESOMA 20 mg capsule twice a day for one week.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will also tell you to take antibiotics for example amoxicillin and clarithromycin.</p><p><strong>To treat stomach ulcers caused by NSAIDs (Non-Steroidal Anti-Inflammatory Drugs):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is one ESOMA 20 mg capsule once a day for 4 to 8 weeks.</p><p><strong>To prevent stomach ulcers if you are taking NSAIDs (Non-Steroidal Anti-Inflammatory Drugs):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is one ESOMA 20 mg capsule once a day.</p><p><strong>To treat too much acid in the stomach caused by a growth in the pancreas (Zollinger-Ellison syndrome):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is ESOMA 40 mg twice a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will adjust the dose depending on your needs and will also decide how long you need to take the medicine for. The maximum dose is 80 mg twice a day.</p><p><strong>Prolonged treatment after prevention of rebleeding of ulcers with intravenous esomeprazole: </strong></p><ul><li>the usual dose is one ESOMA 40 mg capsule once a day for 4 weeks.</li></ul><p><strong><u>Adolescents aged 12 or above</u></strong></p><p><strong>To treat heartburn caused by gastro-oesophageal reflux disease (GORD):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your doctor has found that your food pipe (esophagus) has been slightly damaged, the recommended dose is one ESOMA 40 mg capsule once a day for 4 weeks. Your doctor may tell you to take the same dose for a further 4 weeks if your esophagus has not yet healed.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose once the esophagus has healed is one ESOMA 20 mg capsule once a day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If your esophagus has not been damaged, the recommended dose is one ESOMA 20 mg capsule each day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe liver problems, your doctor may give you a lower dose.</p><p><strong>To treat ulcers caused by&nbsp;<em>Helicobacter pylori</em>&nbsp;infection and to stop them coming back:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The recommended dose is one ESOMA 20 mg capsule twice a day for one week.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will also tell you to take antibiotics for example amoxicillin and clarithromycin.</p><p><strong>Taking this medicine</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take your capsules at any time of the day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take your capsules with food or on an empty stomach.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow your capsules whole with a drink of water. Do not chew or crush the capsules. This is because the capsules contain coated pellets which stop the medicine from being broken down by the acid in your stomach. It is important not to damage the pellets.</p><p><strong>What to do if you have trouble swallowing the capsules</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have trouble swallowing the capsules:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Empty them into a GLASS of still (non-fizzy) water. Do not use any other liquids.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Stir (the mixture will not be clear). Then drink the mixture straight away or within 30 minutes. Always stir the mixture just before drinking it.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; To make sure that you have drunk all of the medicine, rinse the glass very well with half a glass of water and drink it. The solid pieces contain the medicine - do not chew or crush them.</p><ul><li>If you cannot swallow at all, the capsule content can be mixed with some water and put into a syringe. It can then be given to you through a tube directly into your stomach (&lsquo;gastric tube&rsquo;).</li></ul><p><strong>Children under the age of 12 years</strong></p><p>ESOMA capsules are not recommended for children less than 12 years old.</p><p><strong>Elderly</strong></p><p>Dose adjustment is not required in the elderly</p><p><strong>If you take more ESOMA than you should</strong></p><p>If you take more ESOMA than prescribed by your doctor, talk to your doctor or pharmacist straight away.</p><p><strong>If you forget to take ESOMA </strong></p><p>If you forget to take a dose, take it as soon as you remember it. However, if it is almost time for your next dose, skip the missed dose.</p><p>Do not take a double dose (two doses at the same time) to make up for a forgotten dose.</p><p><strong>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>If you notice any of the following serious side effects, stop taking ESOMA and contact a doctor immediately:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden wheezing, swelling of your lips, tongue and throat or body, rash, fainting or difficulties in swallowing (severe allergic reaction).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reddening of the skin with blisters or peeling. There may also be severe blisters and bleeding in the lips, eyes, mouth, nose and genitals. This could be &lsquo;Stevens-Johnson syndrome&rsquo; or &lsquo;toxic epidermal necrolysis&rsquo;.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellow skin, dark urine and tiredness, which can be symptoms of liver problems.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; These effects are rare, and may affect up to 1 in 1,000 people.</p><p>Other side effects include:</p><p><strong><u>Common</u></strong><u>&nbsp;(may affect up to 1 in 10 people)</u></p><p>&bull;&nbsp;&nbsp;&nbsp; Headache.</p><p>&bull;&nbsp;&nbsp;&nbsp; Effects on your stomach or gut: diarrhoea, stomach pain, constipation, wind (flatulence).</p><p>&bull;&nbsp;&nbsp;&nbsp; Feeling sick (nausea) or being sick (vomiting).</p><p>&bull;&nbsp;&nbsp;&nbsp; Benign polyps in the stomach</p><p><strong><u>Uncommon</u></strong><u>&nbsp;(may affect up to 1 in 100 people)</u></p><p>&bull;&nbsp;&nbsp;&nbsp; Swelling of the feet and ankles.</p><p>&bull;&nbsp;&nbsp;&nbsp; Disturbed sleep (insomnia).</p><p>&bull;&nbsp;&nbsp;&nbsp; Dizziness, tingling feelings such as &ldquo;pins and needles&rdquo;, feeling sleepy.</p><p>&bull;&nbsp;&nbsp;&nbsp; Spinning feeling (vertigo).</p><p>&bull;&nbsp;&nbsp;&nbsp; Dry mouth.</p><p>&bull;&nbsp;&nbsp;&nbsp; Changes in blood tests that check how the liver is working.</p><p>&bull;&nbsp;&nbsp;&nbsp; Skin rash, lumpy rash (hives) and itchy skin.</p><p>&bull;&nbsp;&nbsp;&nbsp; Fracture of the hip, wrist or spine (if ESOMA is used in high doses and over long duration).</p><p><strong><u>Rare</u></strong><u>&nbsp;(may affect up to 1 in 1,000 people)</u></p><p>&bull;&nbsp;&nbsp;&nbsp; Blood problems such as a reduced number of white cells or platelets. This can cause weakness, bruising or make infections more likely.</p><p>&bull;&nbsp;&nbsp;&nbsp; Low levels of sodium in the blood. This may cause weakness, being sick (vomiting) and cramps.</p><p>&bull;&nbsp;&nbsp;&nbsp; Feeling agitated, confused or depressed.</p><p>&bull;&nbsp;&nbsp;&nbsp; Taste changes.</p><p>&bull;&nbsp;&nbsp;&nbsp; Eyesight problems such as blurred vision.</p><p>&bull;&nbsp;&nbsp;&nbsp; Suddenly feeling wheezy or short of breath (bronchospasm).</p><p>&bull;&nbsp;&nbsp;&nbsp; An inflammation of the inside of the mouth.</p><p>&bull;&nbsp;&nbsp;&nbsp; An infection called &ldquo;thrush&rdquo; which can affect the gut and is caused by a fungus.</p><p>&bull;&nbsp;&nbsp;&nbsp; Liver problems, including jaundice which can cause yellow skin, dark urine, and tiredness.</p><p>&bull;&nbsp;&nbsp;&nbsp; Hair loss (alopecia).</p><p>&bull;&nbsp;&nbsp;&nbsp; Skin rash on exposure to sunshine.</p><p>&bull;&nbsp;&nbsp;&nbsp; Joint pains (arthralgia) or muscle pains (myalgia).</p><p>&bull;&nbsp;&nbsp;&nbsp; Generally feeling unwell and lacking energy.</p><p>&bull;&nbsp;&nbsp;&nbsp; Increased sweating.</p><p><strong><u>Very rare</u></strong><u>&nbsp;(may affect up to 1 in 10,000 people)</u></p><p>&bull;&nbsp;&nbsp;&nbsp; Changes in blood count including agranulocytosis (lack of white blood cells)</p><p>&bull;&nbsp;&nbsp;&nbsp; Aggression.</p><p>&bull;&nbsp;&nbsp;&nbsp; Seeing, feeling or hearing things that are not there (hallucinations).</p><p>&bull;&nbsp;&nbsp;&nbsp; Severe liver problems leading to liver failure and inflammation of the brain.</p><p>&bull;&nbsp;&nbsp;&nbsp; Sudden onset of a severe rash or blistering or peeling skin. This may be associated with a high fever and joint pains (Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis).</p><p>&bull;&nbsp;&nbsp;&nbsp; Muscle weakness.</p><p>&bull;&nbsp;&nbsp;&nbsp; Severe kidney problems.</p><p>&bull;&nbsp;&nbsp;&nbsp; Enlarged breasts in men.</p><p><strong><u>Not known</u></strong><u>&nbsp;(frequency cannot be estimated from the available data)</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are on ESOMA for more than three months it is possible that the levels of magnesium in your blood may fall. Low levels of magnesium can be seen as fatigue, involuntary muscle contractions, disorientation, convulsions, dizziness or increased heart rate. If you get any of these symptoms, please tell your doctor promptly. Low levels of magnesium can also lead to a reduction in potassium or calcium levels in the blood. Your doctor may decide to perform regular blood tests to monitor your levels of magnesium.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation in the gut (leading to diarrhoea).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, possibly with pain in the joints.</p><p>ESOMA may in very rare cases affect the white blood cells leading to immune deficiency. If you have an infection with symptoms such as fever with a&nbsp;<strong>severely</strong>&nbsp;reduced general condition or fever with symptoms of a local infection such as pain in the neck, throat or mouth or difficulties in urinating, you must consult your doctor as soon as possible so that a lack of white blood cells (agranulocytosis) can be ruled out by a blood test. It is important for you to give information about your medication at this time.</p><p><strong>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, Please tell your doctor or pharmacist.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of the reach and sight of children.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30&deg;C.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store in the original pack to protect from light and moisture.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not use after the expiry date printed on the package</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What ESOMA contains </strong></p><p>The active ingredient is Esomeprazole (as pellets 27.1% w/w).</p><p>Each capsule contains Esomeprazole Magnesium equivalent to Esomeprazole 20 mg or 40 mg.</p><p>Other ingredients are: Hard gelatin capsule shell (size 4 for ESOMA 20 mg &amp; size 3 for ESOMA 40 mg).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What ESOMA looks like and contents of the pack 
Capsules
•	ESOMA 20 mg: Capsule with amethyst coloured cap imprinted with ‘CT12’ and white body, containing white to off-white spherical, enteric coated pellets.
•	ESOMA 40 mg: Capsule with amethyst coloured cap imprinted with ‘CT13’ and white body, containing white to off-white spherical, enteric coated pellets.
Pack: 
•	ESOMA 20 mg: 28 Capsules, 4 strips (7 Capsules/Strip)   & 14 Capsules, 2 strips (7 Capsules/Strip)   
•	ESOMA 40 mg: 28 Capsules, 4 strips (7 Capsules /Strip)   & 14 Capsules, 2 strips (7 Capsules /Strip)  

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer</strong></p><p>Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)</p><p>P.O. Box 442, Riyadh 11411</p><p>Fax: +966 11 265 0505</p><p>Email: contact@riyadhpharma.com</p><p>For any information about this medicinal product, please contact the local representative of marketing authorisation holder:</p><p>Saudi Arabia</p><p>Marketing department</p><p>Riyadh</p><p>Tel: +966 11 265 0111</p><p>Email: marketing@riyadhpharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                3/2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">إيسوما &nbsp;يحتوي على دواء يسمى إيسوميبرازول. هذا ينتمي إلى مجموعة من الأدوية تسمى &quot;مثبطات مضخة البروتون&quot;. وهي تعمل عن طريق تقليل كمية الحامض التي تنتجها معدتك.</p><p dir="RTL">يستخدم إيسوما &nbsp;لعلاج الحالات التالية:</p><p dir="RTL"><u>الكبار</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &quot; الارتجاع المعدي المريئي&quot; (GORD). يحدث عند ارتجاع الحمض من المعدة إلى المريء (الأنبوب الذي يربط الحلق بالمعدة) مما يسبب الألم والالتهاب والحرقة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح في المعدة أو الجزء العلوي من القناة الهضمية (الأمعاء) التي تصاب ببكتيريا تسمى &quot;هيليكوباكتر بيلوري&quot;. إذا كان لديك هذه الحالة، قد يصف الطبيب أيضا المضادات الحيوية لعلاج العدوى وإعطاء الفرصة لشفاء القرحة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرحة المعدة التي تسببها الأدوية التي تسمى مضادات الالتهاب غير الستيرويدية. إيسوما &nbsp;يمكن أن يستخدم أيضا لإيقاف تكون تقرحات المعدة إذا كنت تأخذ مضادات الالتهاب غير الستيرويدية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كثرة الحمض الموجود في المعدة الناجمة عن تورم في البنكرياس (متلازمة زولينجر إليسون).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العلاج لفترة طويلة بعد منع عودة النزف من القرحة بعد استخدام إيسوميبرازول الوريدي.</p><p dir="RTL"><u>المراهقين الذين تتراوح أعمارهم بين 12 سنة وما فوق</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &quot;مرض إرتجاع المريء&quot; (GORD). يحدث هذا عندما يهرب الحمض من المعدة إلى المريء (الأنبوب الذي يربط الحلق إلى معدتك) مما يسبب الألم والالتهاب والحرقة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قرح في المعدة أو الجزء العلوي من القناة الهضمية (الأمعاء) التي تصاب ببكتيريا تسمى &quot;هيليكوباكتر بيلوري&quot;. إذا كان لديك هذه الحالة، قد يصف الطبيب أيضا المضادات الحيوية لعلاج العدوى والسماح للقرحة بالشفاء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول إيسوما </strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية من إيسوميبرازول أو أي من المكونات الأخرى من هذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية من الأدوية الأخرى مثبطات مضخة البروتون (مثل بانتوبرازول، لانزوبرازول، رابيبرازول، أوميبرازول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول دواء يحتوي على نلفينافير (المستخدم لعلاج عدوى فيروس نقص المناعة البشرية).</p><p dir="RTL">لا تتناول إيسوما &nbsp;إذا كان أي مما سبق ينطبق عليك. إذا لم تكن متأكدا، تحدث مع طبيبك أو الصيدلي قبل تناول إيسوما .</p><p dir="RTL"><strong>الاحتياطات عند تناول إيسوما </strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلاني قبل تناول إيسوما :</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل خطيرة في الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل خطيرة في الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك في أي وقت مضى ردة فعل بالجلد بعد العلاج بدواء مماثل لإيسوما &nbsp;والذي يقلل من حمض المعدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان من المقرر أن يكون لديك فحص دم معين (كروموغرانين A).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك نقص فيتامين ب 12 .</p><p dir="RTL">إيسوما &nbsp;قد يخفي أعراض الأمراض الأخرى. <strong>لذلك، إذا كان أي من الأعراض التالية يحدث لك قبل البدء في تناول إيسوما &nbsp;أو أثناء تناوله، تحدث مع طبيبك على الفور:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفقد الكثير من الوزن دون سبب ولديك مشاكل في البلع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحدث لك آلام في المعدة أو عسر الهضم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بدأت في تقيؤ الطعام أو دم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تخرج براز أسود (البراز الملطخة بالدم).</p><p dir="RTL">إذا تم وصف إيسوما &nbsp;لك &quot;عند الحاجة&quot; يجب عليك الاتصال بطبيبك إذا استمرت الأعراض التي تحدث لك أو تغيرت في طابعها.</p><p dir="RTL">تناول مثبط مضخة البروتون مثل إيسوما ، وخاصة على مدى فترة أكثر من سنة واحدة، قد يزيد قليلا من خطر الكسور في عظام الورك والمعصم أو العمود الفقري. أخبر طبيبك إذا كان لديك هشاشة العظام أو إذا كنت تأخذ الستيرويدات (التي يمكن أن تزيد من خطر هشاشة العظام).</p><p dir="RTL">إذا حدث لك طفح على جلدك، وخاصة في المناطق المعرضة لأشعة الشمس أخبر طبيبك بأسرع ما يمكن، كما أنك قد تحتاج إلى إيقاف علاجك بإيسوما . تذكر أن تخبر طبيبك أيضا عن أي آثار سيئة أخرى مثل الألم في المفاصل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى</strong><strong> </strong><strong>و</strong><strong> </strong><strong>إيسوما </strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، قد تناولت مؤخرا أو قد تتناول أي أدوية أخرى. وهذا يشمل الأدوية التي تشتريها بدون وصفة طبية. وذلك لأن إيسوما&nbsp; يمكن أن يؤثر على طريقة عمل بعض الأدوية وبعض الأدوية يمكن أن يكون لها تأثير على إيسوما .</p><p dir="RTL">لا تتناول كبسولات إيسوما&nbsp; إذا كنت تتناول دواء يحتوي على نلفينافير (يستخدم لعلاج عدوى فيروس نقص المناعة البشرية).</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أي من الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اتازانافير (المستخدم لعلاج عدوى فيروس نقص المناعة البشرية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلوبيدوغريل (يستخدم لمنع جلطات الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيتوكونازول، إيتراكونازول أو فوريكونازول (يستخدم لعلاج الالتهابات الناجمة عن الفطريات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إرلوتينيب (يستخدم لعلاج السرطان).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيتالوبرام، إيميبرامين أو كلوميبرامين (يستخدم لعلاج الاكتئاب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الديازيبام (يستخدم لعلاج القلق، واسترخاء العضلات أو في الصرع).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفينيتوين (يستخدم في الصرع). إذا كنت تتناول الفينيتوين، سيحتاج طبيبك إلى ملاحظتك عند البدء أو التوقف عن تناول إيسوما .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تستخدم لتقليل لزوجة الدم، مثل الوارفارين. قد يحتاج طبيبك إلى مراقبتك عند البدء أو التوقف عن تناول إيسوما&nbsp; .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيلوستازول (يستخدم لعلاج العرج المتقطع - ألم في ساقيك عند المشي الذي يسببه عدم كفاية إمدادات الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيسابريد (يستخدم لعسر الهضم والحرقة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسين (يستخدم لمشاكل القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثوتريكسيت (وهو دواء كيميائي يستخدم بجرعات عالية لعلاج السرطان) - إذا كنت تتناول جرعة عالية من الميثوتريكسيت، قد &nbsp;يوقف طبيبك استخدامك لعلاج إيسوما&nbsp; مؤقتا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تاكروليموس (يستخدم في زرع الأعضاء).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (يستخدم لعلاج السل).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون (هيبيريكوم بيرفوراتوم) (تستخدم لعلاج الاكتئاب).</p><p dir="RTL">إذا كان طبيبك قد وصف المضادات الحيوية أموكسيسيلين و كلاريثروميسين وكذلك إيسوما&nbsp; لعلاج القرحة الناجمة عن عدوى هيليكوباكتر بيلوري، فمن المهم جدا أن تخبر طبيبك عن أي أدوية أخرى كنت تتناولها.</p><p dir="RTL"><strong>تناول إيسوما </strong><strong>&nbsp;مع الطعام والشراب</strong></p><p dir="RTL">يمكنك أن تتناول كبسولاتك مع الطعام أو على معدة فارغة.</p><p dir="RTL"><strong>ال</strong><strong>حمل و</strong><strong>الرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">إذا كنتي حاملا، تعتقدين أنك قد تكونين حاملا أو تخططين لولادة طفل، اطلبي من الطبيب أو الصيدلي الحصول على المشورة قبل تناول هذا الدواء. سوف يقرر طبيبك ما إذا كان بإمكانك تناول إيسوما&nbsp; خلال هذا الوقت. ومن غير المعروف ما إذا كان إيسوما&nbsp; يفرز مع حليب الثدي. لذلك، يجب ألا تأخذي إيسوما&nbsp; إذا كنتي ترضعين طفلك رضاعة طبيعية.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">ليس من المرجح أن يؤثر إيسوما&nbsp; في القدرة على قيادة أو استخدام أي أدوات أو آلات. ومع ذلك، قد تحدث آثار جانبية مثل الدوخة وعدم وضوح الرؤية بشكل نادر أو غير معتاد (انظر القسم 4). إذا تأثرت، يجب ألا تقود سيارة أو تستخدم الآلات.</p><p dir="RTL"><strong>معلومات هامة</strong></p><p dir="RTL"><strong>إ</strong><strong>ي</strong><strong>سوما&nbsp; يحتوي على السكروز</strong></p><p dir="RTL">إذا قيل لك من قبل طبيبك أن لديك عدم تحمل لبعض السكريات، تحدث إلى طبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;دائما تناول هذا الدواء تماما كما قال لك الطبيب أو الصيدلي. تحقق من طبيبك أو الصيدلي إذا كنت غير متأكد.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول هذا الدواء لفترة طويلة، فسوف يود طبيبك أن يلاحظك (خاصة إذا كنت تتناول الدواء لمدة تزيد عن عام).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أخبرك طبيبك بأن تتناول ھذا الدواء عند الحاجة، أخبر طبيبك إذا تغيرت الأعراض.</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف يخبرك طبيبك بعدد الكبسولات التي يجب أخذها ومدة أخذها. هذا يعتمد على حالتك، كم عمرك وجودة عمل الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم إعطاء الجرعات الموصى بها كالتالي:</p><p dir="RTL"><strong><u>البالغين الذين اعمارهم من عمر 18 عاما فما فوق</u></strong></p><p dir="RTL"><strong>لعلاج حرقة المعدة الناجمة عن مرض الارتجاع المعدي المريئي (</strong><strong>GORD</strong><strong>):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا وجد طبيبك أن أنبوب الطعام لديك (المريء) قد أصيب بأضرار طفيفة، فإن الجرعة الموصى بها هي كبسولة واحدة من إيسوما&nbsp; 40 ملجم مرة واحدة يوميا لمدة 4 أسابيع. قد يخبرك طبيبك أن تأخذ نفس الجرعة لمدة 4 أسابيع أخرى إذا لم يلتئم المريء لديك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بھا بمجرد أن یلتئم المريء ھي كبسولة واحدة من إيسوما&nbsp; 20 ملجم مرة واحدة في الیوم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم يتم تلف المريء، الجرعة الموصى بها هي كبسولة واحدة من إيسوما &nbsp;20 ملجم واحدة يوميا. وبمجرد أن يتم التحكم في الحالة، قد يخبرك الطبيب بأن تتناول الدواء عند الحاجة إليه، بحد أقصى كبسولة إيسوما&nbsp; 20 ملجم واحدة يوميا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا کنت تعاني من مشاكل شديدة في الکبد، قد يعطيك الطبيب جرعة أقل.</p><p dir="RTL"><strong>لعلاج القرحة التي تسببها عدوى هيليكوباكتر بيلوري وايقاف عودتها:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها هي كبسولة واحدة من إيسوما&nbsp; 20 ملجم مرتين في اليوم لمدة أسبوع واحد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف یخبرك طبيبك أیضا بتناول المضادات الحیویة علی سبيل المثال أموکسیسیلین وکلاریثرومیسین.</p><p dir="RTL"><strong>لعلاج قرحة المعدة الناجمة عن مضادات الالتهاب غير الستيرويدية (الأدوية اللاستيرويدية المضادة للالتهابات):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها هي كبسولة واحدة من إيسوما&nbsp; 20 ملجم مرة واحدة في اليوم لمدة 4-8 أسابيع.</p><p dir="RTL"><strong>لمنع قرحة المعدة إذا كنت تأخذ مضادات الالتهاب غير الستيرويدية (الأدوية اللاستيرويدية المضادة للالتهابات):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها هي كبسولة واحدة من إيسوما&nbsp; 20 ملجم مرة واحدة في اليوم.</p><p dir="RTL"><strong>لعلاج كثرة حمض في المعدة الناجمة عن تورم في البنكرياس (متلازمة زولينجر إليسون):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها هي كبسولة واحدة من إيسوما&nbsp; 40 ملجم مرتين في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم طبيبك بتعديل الجرعة تبعا لاحتياجاتك وسيقرر أيضا كم من الوقت تحتاج لتناول الدواء. الجرعة القصوى هي 80 ملجم مرتين في اليوم.</p><p dir="RTL"><strong>العلاج لفترة طويلة بعد منع عودة النزف من القرحة بعد استخدام إيسوميبرازول الوريدي</strong><strong>:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة المعتادة هي كبسولة واحدة من إيسوما&nbsp; 40 ملجم مرة واحدة في اليوم لمدة 4 أسابيع.</p><p dir="RTL"><strong><u>المراهقين الذين أعمارهم من عمر 12 أو أعلى</u></strong></p><p dir="RTL"><strong>لعلاج حرقة المعدة الناجمة عن مرض إرتجاع المريء (</strong><strong>GORD</strong><strong>):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا وجد طبيبك أن أنبوب الطعام لديك (المريء) قد أصيب بأضرار طفيفة، فإن الجرعة الموصى بها هي كبسولة واحدة من إيسوما&nbsp; 40 ملجم مرة واحدة يوميا لمدة 4 أسابيع. قد يخبرك طبيبك أن تأخذ نفس الجرعة لمدة 4 أسابيع أخرى إذا لم يلتئم المريء بعد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها بمجرد شفاء المريء هي كبسولة واحدة من إيسوما&nbsp; 20 ملجم مرة واحدة في اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا لم يتم تلف المريء، فإن الجرعة الموصى بها هي كبسولة واحدة من إيسوما&nbsp; 20 ملجم مرة واحدة كل يوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا کنت تعاني من مشاکل شديدة في الکبد، قد یصف لك الطبیب جرعة أقل.</p><p dir="RTL"><strong>لعلاج القرحة التي تسببها عدوى هيليكوباكتر بيلوري وايقاف عودتها:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الجرعة الموصى بها هي كبسولة واحدة من إيسوما&nbsp; 20 ملجم مرتين في اليوم لمدة أسبوع واحد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سوف یخبرك طبیبك أیضا بأخذ المضادات الحیویة علی سبیل المثال أموکسیسیلین وکلاریثرومیسین.</p><p dir="RTL"><strong>تناول هذا الدواء</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناول الكبسولات في أي وقت من اليوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناول كبسولاتك مع الطعام أو على معدة فارغة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلاع الكبسولات بكاملها مع الماء. لا تمضغ أو تسحق الكبسولات. وذلك لأن الكبسولات تحتوي على كريات مغلفة التي تمنع تكسرالدواء بواسطة الحمض في معدتك. من المهم عدم إلحاق الضرر بالكريات.</p><p dir="RTL"><strong>ماذا تفعل إذا كان لديك مشكلة في بلع الكبسولات</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا کنت تعاني من صعوبة في بلع الكبسولات:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; افرغها في كوب من المياه (غير الغازية). لا تستخدم أي سوائل أخرى.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مع التحريك (الخليط لن يكون شفافا). ثم اشرب الخليط على الفور أو في غضون 30 دقيقة. دائما حرك الخليط قبل شربه.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; للتأكد من شرب كل الدواء، أشطف الكوب جيدا مع نصف كوب من الماء واشربه .الأجزاء الصلبة تحتوي على الدواء لا تمضغها أو تسحقها .</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت لا تستطيع البلع على الإطلاق، يمكن خلط محتوى الكبسولة مع بعض الماء ووضعها في حقنة. ويمكن بعد ذلك أن تعطى لك من خلال أنبوب مباشرة في المعدة (&#39;أنبوب المعدة&#39;).</p><p dir="RTL"><strong>الأطفال دون سن 12 عاما</strong></p><p dir="RTL">لا ينصح بكبسولات إيسوما للأطفال أقل من 12 سنة.</p><p dir="RTL"><strong>كبار السن</strong></p><p dir="RTL">ليس من الضروري تعديل الجرعة لكبار السن.</p><p dir="RTL"><strong>إذا تناولت إيسوما &nbsp;أكثر مما يجب</strong><br />إذا تناولت إيسوما&nbsp; أكثر مما وصفه طبيبك لك، تحدث إلى طبيبك أو الصيدلي مباشرة.</p><p dir="RTL"><strong>إذا نسيت تناول أقراص إيسوما &nbsp;الخاصة بك</strong></p><p dir="RTL">إذا نسيت تناول جرعة، تناولها عند تذكرها. ومع ذلك، إذا حان الوقت تقريبا للجرعة التالية، تخطي الجرعة الفائتة.</p><p dir="RTL">لا تأخذ جرعة مضاعفة (جرعتان في نفس الوقت) لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن تسبب كبسولات إيسوما &nbsp;آثارا جانبية على الرغم من أن هذه الآثار لا تحدث لكل شخص.</p><p dir="RTL">إذا لاحظت أي من الآثار الجانبية الخطيرة التالية، توقف عن تناول إيسوما&nbsp; واتصل بالطبيب فورا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأزيز المفاجئ، وتورم الشفتين، واللسان والحلق أو الجسم، والطفح الجلدي، وإغماء أو صعوبات في البلع (ردة فعل تحسسية شديدة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد مع ظهور بثور أو تقشير. قد يكون هناك أيضا بثور شديدة ونزيف في الشفتين والعينين والفم والأنف والأعضاء التناسلية. هذا يمكن أن يكون &quot;متلازمة ستيفنز جونسون&quot; أو &quot; تقشر الأنسجة المتموتة البشروية التسممي&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد ، البول الداكن والتعب الذي يمكن أن يكون أعراض لمشاكل الكبد.</p><p dir="RTL">هذه الآثار الجانبية نادرة، وقد تؤثر على ما يصل إلى 1 من كل1000 شخص.</p><p dir="RTL">الآثار الجانبية الأخرى تتضمن:</p><p dir="RTL"><strong><u>شائعة</u></strong><u> (قد تؤثر على ما يصل إلى 1 من كل 10 أشخاص)</u></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الراس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آثار على معدتك أو الأمعاء: الإسهال، آلام في المعدة، والإمساك، والريح (انتفاخ البطن).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالمرض (الغثيان) أو الاعياء (القيء).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاورام الحميدة في المعدة .</p><p dir="RTL"><strong><u>غير شائعة</u></strong><u> (قد تؤثر على ما يصل إلى 1 من كل 100 شخص)</u></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم القدمين والكاحلين.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطراب النوم (الأرق).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة، مشاعر وخز مثل &quot;الدبابيس والإبر&quot;، والشعور بالنعاس.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات في اختبارات الدم التي تتحقق من كيفية عمل الكبد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، طفح جلدي عقدي (أرتيكاريا) وحكة في الجلد.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كسر في الورك، المعصم أو العمود الفقري (إذا تم استخدام إيسوما&nbsp; في جرعات عالية وعلى مدى فترة طويلة).</p><p dir="RTL"><strong><u>نادرة</u></strong><u> (قد تؤثر على ما يصل إلى 1 من كل 1000 شخص)</u></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الدم مثل انخفاض عدد الخلايا البيضاء أو الصفائح الدموية. هذا يمكن أن يسبب ضعف، كدمات أو جعل الالتهابات أكثر احتمالا.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات الصوديوم في الدم. هذا قد يسبب الضعف، والمرض (القيء) والتشنجات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتهيج أو الخلط أو الاكتئاب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغييرات بالتذوق.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل البصر مثل عدم وضوح الرؤية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور فجأة بضيق أو قصر التنفس (تشنج قصبي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في داخل الفم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى تسمى &quot;القلاع&quot; التي يمكن أن تؤثر على القناة الهضمية وتسببها الفطريات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل بالكبد وتشمل الصفراء التي تسبب اصفرار الجلد، بول داكن والتعب.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشعر (الثعلبة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي عند التعرض للشمس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام بالمفاصل (ألم مفصلي) أو آلام بالعضلات (ألم عضلي).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احساس عام بالتوعك فقدان الطاقة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة التعرق</p><p dir="RTL"><strong><u>نادرة جدا</u></strong><u> (قد تؤثر على ما يصل إلى 1 من كل 10000 شخص)</u></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في تعداد الدم بما في ذلك ندرة المحببات (نقص خلايا الدم البيضاء)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;العدوانية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رؤية أو السمع أو الشعور بأشياء ليست موجودة (الهلوسة)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الكبد الشديدة التي تؤدي إلى فشل الكبد والتهاب الدماغ.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور مفاجئ لطفح جلدي حاد أو تقشير للبشرة . هذه قد تترافق مع ارتفاع في درجة الحرارة وآلام المفاصل (حمامي عديدة الأشكال، &nbsp;متلازمة ستيفنز جونسون، تقشر الأنسجة المتموتة البشروية التسممي)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الكلى الشديدة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الثدي في الرجال.</p><p dir="RTL"><u>غير معروف (لا يمكن تقدير التكرار من البيانات المتاحة</u>)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول إيسوما &nbsp;لأكثر من ثلاثة أشهر فمن الممكن أن تنخفض مستويات المغنيسيوم في الدم. يمكن أن ترى المستويات المنخفضة من المغنيسيوم في صورة التعب، تقلصات العضلات اللاإرادية، والارتباك، والتشنجات، والدوخة أو زيادة معدل ضربات القلب. إذا ظهر عليك أي من هذه الأعراض، يرجى إخبار الطبيب على وجه السرعة. انخفاض مستويات المغنيسيوم يمكن أن يؤدي أيضا إلى انخفاض في مستويات البوتاسيوم أو الكالسيوم في الدم. قد يقرر طبيبك إجراء فحوص دم منتظمة لمراقبة مستويات المغنيسيوم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في الأمعاء (مما يؤدي إلى الإسهال)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي، ربما مع ألم في المفاصل.</p><p dir="RTL">قد تؤثر كبسولات إيسوما&nbsp; في حالات نادرة جدا على خلايا الدم البيضاء المؤدية إلى نقص المناعة. إذا كان لديك عدوى مع أعراض مثل الحمى مع انخفاض شديد في الحالة العامة أو الحمى مع أعراض عدوى محلية مثل ألم في الرقبة والحلق أو الفم أو صعوبات في التبول، يجب عليك استشارة الطبيب في أقرب وقت ممكن بحيث يمكن استبعاد النقص في خلايا الدم البيضاء (ندرة المحببات) من خلال اختبار الدم. من المهم بالنسبة لك أن تعطي معلومات عن الدواء الخاص بك في هذا الوقت.</p><p><strong>إذا أصبحت أي من الآثار الجانبية خطيرة، أو إذا لاحظت أي آثار جانبية غير المذكورة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp; يحفظ بعيدا عن متناول أيدي ونظر الأطفال.</p><p dir="RTL">-&nbsp; &nbsp;يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">-&nbsp; &nbsp;يحفظ في العبوة الأصلية للحماية من الضوء الرطوبة.</p><p dir="RTL">-&nbsp; لا تستخدم إيسوما &nbsp;بعد تاريخ انتهاء الصلاحية المدون على الشريط وعلى الكرتون.</p><p dir="RTL">-&nbsp; لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. هذه التدابير تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماهي محتويات إيسوما :</strong></p><p dir="RTL">المادة الفعالة هي إيسوميبرازول (كريات 27.1٪)</p><p dir="RTL">حيث تحتوي كل كبسولة على إيسوميبرازول مغنيسيوم ما يعادل إيسوميبرازول 20 ملجم أو 40 ملجم.</p><p dir="RTL">المكونات الأخرى هي: قشرة الكبسولة من الجيلاتين الصلب (مقاس 4 في إيسوما&nbsp; 20 ملجم و مقاس 3 في إيسوما&nbsp; 40 ملجم).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو الشكل الصيدلاني ل</strong><strong>إيسوما </strong><strong>&nbsp;ووصفه وحجم عبوته</strong><strong> :</strong></p><p dir="RTL"><strong>الكبسولة: </strong></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp; </strong><strong>إيسوما&nbsp; 20 ملجم:</strong> كبسولة لها غطاء أرجواني اللون مطبوع عليه &quot;CT12&quot; ولها جسم أبيض، تحتوي على كريات مغلفة تغليف معوي لونها أبيض إلى أبيض داكن.</p><p dir="RTL">&bull;&nbsp;&nbsp; <strong>إيسوما&nbsp; 40 ملجم:</strong> كبسولة لها غطاء أرجواني اللون مطبوع عليه &quot;CT13&quot; ولها جسم أبيض، تحتوي على كريات مغلفة تغليف معوي لونها أبيض إلى أبيض داكن.</p><p dir="RTL">&nbsp;<strong>العبوة:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp; <strong>إيسوما&nbsp; 20 ملجم:</strong> 28 كبسولة، 4 شرائط (7 كبسولة / شريط) و 14 كبسولة ، 2 شريط (7 كبسولة / شريط)</p><p dir="RTL">&bull;&nbsp;&nbsp; <strong>إيسوما&nbsp; 40 ملجم:</strong> 28 كبسولة، 4 شرائط (7 كبسولة / شريط) و 14 كبسولة ، 2 شريط (7 كبسولة / شريط)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>اسم وعنوان مالك رخصة التسويق والمصنع</strong></p><p dir="RTL">شركة المنتجات الطبية والتجميلية المحدودة (الرياض فارما)</p><p dir="RTL">ص.ب. 442 الرياض 11411</p><p dir="RTL">فاكس: 966112650505+</p><p dir="RTL">البريد الإلكتروني: contact@riyadhpharma.com</p><p dir="RTL"><em>لأية معلومات عن هذا المنتج الطبي، يرجى الاتصال على صاحب الترخيص والتسويق:</em></p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">قسم التسويق</p><p dir="RTL">الرياض</p><p dir="RTL">تلفون: 966112650111+</p><p dir="RTL">البريد الإلكتروني: marketing@riyadhpharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            3/2018
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Esoma Capsule 20 mg
Esoma Capsule 40 mg

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains Esomeprazole Magnesium DR pellets 22.7% w/w
For full list of excepients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard Gelatin Capsule

ESOMA 20 mg: Capsule with amethyst coloured cap imprinted with ‘CT12’ and white body, containing white to off-white spherical, enteric coated pellets.
ESOMA 40 mg: Capsule with amethyst coloured cap imprinted with ‘CT13’ and white body, containing white to off-white spherical, enteric coated pellets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Adults</u></p><p><strong>Gastroesophageal Reflux Disease (GORD)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treatment of erosive reflux oesophagitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; long-term management of patients with healed oesophagitis to prevent relapse</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptomatic treatment of gastroesophageal reflux disease (GORD)</p><p><strong>In combination with appropriate antibacterial therapeutic regimens for the eradication of&nbsp;<em>Helicobacter pylori&nbsp;</em>and</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; healing of&nbsp;<em>Helicobacter pylori&nbsp;</em>associated duodenal ulcer and</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prevention of relapse of peptic ulcers in patients with&nbsp;<em>Helicobacter pylori&nbsp;</em>associated ulcers</p><p><strong>Patients requiring continued NSAID therapy</strong></p><p>Healing of gastric ulcers associated with NSAID therapy.</p><p>Prevention of gastric and duodenal ulcers associated with NSAID therapy, in patients at risk.</p><p><strong>Prolonged treatment after IV induced prevention of rebleeding of peptic ulcers.</strong></p><p><strong>Treatment of Zollinger Ellison Syndrome</strong></p><p><u>Adolescents from the age of 12 years</u></p><p><strong>Gastro-Oesophageal Reflux Disease (GORD)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treatment of erosive reflux oesophagitis</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; long-term management of patients with healed oesophagitis to prevent relapse</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptomatic treatment of gastro-oesophageal reflux disease (GORD)</p><p><strong>In combination with antibiotics in treatment of duodenal ulcer caused by&nbsp;<em>Helicobacter pylori</em></strong></p><ul></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong></p><p><u>Adults and adolescents from the age of 12 years</u></p><p><strong>Gastroesophageal Reflux Disease (GORD)</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>treatment of erosive reflux oesophagitis</u></p><p>40 mg once daily for 4 weeks.</p><p>An additional 4 weeks treatment is recommended for patients in whom oesophagitis has not healed or who have persistent symptoms.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>long-term management of patients with healed oesophagitis to prevent relapse</u></p><p>20 mg once daily.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>symptomatic treatment of gastroesophageal reflux disease (GORD)</u></p><p>20 mg once daily in patients without oesophagitis. If symptom control has not been achieved after 4 weeks, the patient should be further investigated. Once symptoms have resolved, subsequent symptom control can be achieved using 20 mg once daily. In adults, an on demand regimen taking 20 mg once daily, when needed, can be used. In NSAID treated patients at risk of developing gastric and duodenal ulcers, subsequent symptom control using an on demand regimen is not recommended.</p><p><u>Adults</u></p><p><strong>In combination with appropriate antibacterial therapeutic regimens for the eradication of&nbsp;<em>Helicobacter pylori&nbsp;</em>and</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>healing of&nbsp;<em>Helicobacter pylori&nbsp;</em>associated duodenal ulcer and</u></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>prevention of relapse of peptic ulcers in patients with&nbsp;<em>Helicobacter pylori&nbsp;</em>associated ulcers.</u></p><p>20 mg Esoma with 1 g amoxicillin and 500 mg clarithromycin, all twice daily for 7 days.</p><p><strong>Patients requiring continued NSAID therapy</strong></p><p>Healing of gastric ulcers associated with NSAID therapy: The usual dose is 20 mg once daily. The treatment duration is 4-8 weeks.</p><p>Prevention of gastric and duodenal ulcers associated with NSAID therapy in patients at risk: 20 mg once daily.</p><p><strong>Prolonged treatment after IV induced prevention of rebleeding of peptic ulcers</strong></p><p>40 mg once daily for 4 weeks after IV induced prevention of rebleeding of peptic ulcers.</p><p><strong>Treatment of Zollinger Ellison Syndrome</strong></p><p>The recommended initial dosage is Esoma 40 mg twice daily. The dosage should then be individually adjusted and treatment continued as long as clinically indicated. Based on the clinical data available, the majority of patients can be controlled on doses between 80 to 160 mg esomeprazole daily. With doses above 80 mg daily, the dose should be divided and given twice daily.</p><p><strong><em><u>Paediatric population</u></em></strong></p><p><u>Adolescents from the age of 12 years</u></p><p><strong>Treatment of duodenal ulcer caused by&nbsp;<em>Helicobacter pylori</em></strong></p><p>When selecting appropriate combination therapy, consideration should be given to official national, regional and local guidance regarding bacterial resistance, duration of treatment (most commonly 7 days but sometimes up to 14 days), and appropriate use of antibacterial agents. The treatment should be supervised by a specialist.</p><p>The posology recommendation is:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Posology</p></td></tr><tr><td style="vertical-align:top"><p>30 - 40 kg</p></td><td style="vertical-align:top"><p>Combination with two antibiotics: Esoma 20 mg, amoxicillin 750 mg and clarithromycin 7.5 mg/kg body weight are all administered together twice daily for one week.</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 40 kg</p></td><td style="vertical-align:top"><p>Combination with two antibiotics: Esoma 20 mg, amoxicillin 1 g and clarithromycin 500 mg are all administered together twice daily for one week.</p></td></tr></tbody></table><p><strong>Children below the age of 12 years</strong></p><p>Esoma should not be used in children younger than 12 years since no data is available.</p><p><strong>Patients with impaired renal function</strong></p><p>Dose adjustment is not required in patients with impaired renal function. Due to limited experience in patients with severe renal insufficiency, such patients should be treated with caution (see section 5.2).</p><p><strong>Patients with impaired hepatic function</strong></p><p>Dose adjustment is not required in patients with mild to moderate liver impairment. For patients with severe liver impairment, a maximum dose of 20 mg Esoma should not be exceeded (see section 5.2).</p><p><strong>Elderly patients</strong></p><p>Dose adjustment is not required in the elderly.</p><p>Do not eat the desiccant capsule provided in the container.</p><p>Method of administration</p><p>The capsules should be swallowed whole with some water. The capsules should not be chewed or crushed.</p><p>For patients who have difficulty in swallowing, the capsules can also be opened and the pellets mixed in half a glass of non-carbonated water. No other liquids should be used as the enteric coating may be dissolved. Drink the water with the pellets immediately or within 30 minutes. Rinse the glass with half a glass of water and drink. The pellets must not be chewed or crushed.</p><p>For patients who cannot swallow, the capsules can be opened and pellets mixed in non-carbonated water and administered through a gastric tube. It is important that the appropriateness of the selected syringe and tube is carefully tested before use (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, to substituted benzimidazoles or to any of the excipients listed in section 6.1.
Esomeprazole should not be used concomitantly with nelfinavir (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the presence of any alarm symptom (e.g. significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melaena) and when gastric ulcer is suspected or present, malignancy should be excluded, as treatment with Esoma may alleviate symptoms and delay diagnosis.</p><p><u>Long term use</u></p><p>Patients on long-term treatment (particularly those treated for more than a year) should be kept under regular surveillance.</p><p><u>On demand treatment</u></p><p>Patients on on-demand treatment should be instructed to contact their physician if their symptoms change in character.</p><p><em><u>Helicobacter pylori eradication</u></em></p><p>When prescribing esomeprazole for eradication of&nbsp;<em>Helicobacter pylori</em>, possible drug interactions for all components in the triple therapy should be considered. Clarithromycin is a potent inhibitor of CYP3A4 and hence contraindications and interactions for clarithromycin should be considered when the triple therapy is used in patients concurrently taking other drugs metabolized via CYP3A4 such as cisapride.</p><p><u>Gastrointestinal infections</u></p><p>Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as&nbsp;<em>Salmonella</em>&nbsp;and&nbsp;<em>Campylobacter</em>&nbsp;(see section 5.1).</p><p><u>Absorption of vitamin B12</u></p><p>Esomeprazole, as all acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin) due to hypo- or achlorhydria. This should be considered in patients with reduced body stores or risk factors for reduced vitamin B12 absorption on long-term therapy.</p><p><u>Hypomagnesaemia</u></p><p>Severe hypomagnesaemia has been reported in patients treated with proton pump inhibitors (PPIs) like esomeprazole for at least three months, and in most cases for a year. Serious manifestations of hypomagnesaemia such as fatigue, tetany, delirium, convulsions, dizziness and ventricular arrhythmia can occur but they may begin insidiously and be overlooked. In most affected patients, hypomagnesaemia improved after magnesium replacement and discontinuation of the PPI.</p><p>For patients expected to be on prolonged treatment or who take PPIs with digoxin or drugs that may cause hypomagnesaemia (e.g. diuretics), healthcare professionals should consider measuring magnesium levels before starting PPI treatment and periodically during treatment.</p><p><u>Risk of fracture</u></p><p>Proton pump inhibitors, especially if used in high doses and over long durations (&gt;1 year), may modestly increase the risk of hip, wrist and spine fracture, predominantly in the elderly or in presence of other recognized risk factors. Observational studies suggest that proton pump inhibitors may increase the overall risk of fracture by 10-40%. Some of this increase may be due to other risk factors. Patients at risk of osteoporosis should receive care according to current clinical guidelines and they should have an adequate intake of vitamin D and calcium.</p><p><u>Subacute cutaneous lupus erythematosus (SCLE)</u></p><p>Proton pump inhibitors are associated with very infrequent cases of SCLE. If lesions occur, especially in sun-exposed areas of the skin, and if accompanied by arthralgia, the patient should seek medical help promptly and the health care professional should consider stopping Esoma. SCLE after previous treatment with a proton pump inhibitor may increase the risk of SCLE with other proton pump inhibitors.</p><p>Systemic lupus erythematosus (SLE) is less commonly reported than SCLE in patients receiving PPIs. PPI associated SLE is usually milder than non-drug induced SLE. Onset of SLE typically occurred within days to years after initiating treatment primarily in patients ranging from young adults to the elderly. The majority of patients presented with rash; however, arthralgia and cytopenia were also reported.</p><p>Avoid administration of PPIs for longer than medically indicated. If signs or symptoms consistent with SCLE or SLE are noted in patients receiving esomeprazole, discontinue the drug and refer the patient to the appropriate specialist for evaluation. Most patients improve with discontinuation of the PPI alone in 4 to 12 weeks. Serological testing (e.g., ANA) may be positive and elevated serological test results may take longer to resolve than clinical manifestations.</p><p><u>Combination with other medicinal products</u></p><p>Co-administration of esomeprazole with atazanavir is not recommended (see section 4.5). If the combination of atazanavir with a proton pump inhibitor is judged unavoidable, close clinical monitoring is recommended in combination with an increase in the dose of atazanavir to 400 mg with 100 mg of ritonavir; esomeprazole 20 mg should not be exceeded.</p><p>Esomeprazole is a CYP2C19 inhibitor. When starting or ending treatment with esomeprazole, the potential for interactions with drugs metabolized through CYP2C19 should be considered. An interaction is observed between clopidogrel and esomeprazole (see section 4.5). The clinical relevance of this interaction is uncertain. As a precaution, concomitant use of esomeprazole and clopidogrel should be discouraged.</p><p>When prescribing esomeprazole for on demand therapy, the implications for interactions with other pharmaceuticals, due to fluctuating plasma concentrations of esomeprazole should be considered. See section 4.5.</p><p><u>Interference with laboratory tests</u></p><p>Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumours. To avoid this interference, esomeprazole treatment should be stopped for at least 5 days before CgA measurements (see section 5.1). If CgA and gastrin levels have not returned to reference range after initial measurement, measurements should be repeated 14 days after cessation of proton pump inhibitor treatment.</p><p><u>Acute Interstitial Nephritis</u></p><p>Acute interstitial nephritis has been observed in patients taking PPIs including esomeprazole. Acute interstitial nephritis may occur at any point during PPI therapy and is generally attributed to an idiopathic hypersensitivity reaction. Discontinue esomeprazole if acute interstitial nephritis develops.</p><p><u>Clostridium difficile-Associated Diarrhea</u></p><p>Published observational studies suggest that PPI therapy like esomeprazole may be associated with an increased risk of Clostridium difficile-associated diarrhea, especially in hospitalized patients. This diagnosis should be considered for diarrhea that does not improve.</p><p>Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;<u>Effects of esomeprazole on the pharmacokinetics of other drugs</u></p><p><em><u>Protease inhibitors</u></em></p><p>Omeprazole has been reported to interact with some protease inhibitors. The clinical importance and the mechanisms behind these reported interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the protease inhibitors. Other possible interaction mechanisms are via inhibition of CYP2C19.</p><p>For atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole and concomitant administration is not recommended. Co-administration of omeprazole (40 mg once daily) with atazanavir 300 mg/ritonavir 100 mg to healthy volunteers resulted in a substantial reduction in atazanavir exposure (approximately 75% decrease in AUC, C<sub>max</sub>&nbsp;and C<sub>min</sub>). Increasing the atazanavir dose to 400 mg did not compensate for the impact of omeprazole on atazanavir exposure. The co-administration of omeprazole (20 mg qd) with atazanavir 400 mg/ritonavir 100 mg to healthy volunteers resulted in a decrease of approximately 30% in the atazanavir exposure as compared with the exposure observed with atazanavir 300 mg/ritonavir 100 mg qd without omeprazole 20 mg qd. Co-administration of omeprazole (40 mg qd) reduced mean nelfinavir AUC, C<sub>max</sub>&nbsp;and C<sub>min</sub>&nbsp;by 36&ndash;39 % and mean AUC, C<sub>max</sub>&nbsp;and C<sub>min</sub>&nbsp;for the pharmacologically active metabolite M8 was reduced by 75-92%.<strong>&nbsp;</strong>Due to the similar pharmacodynamics effects and pharmacokinetic properties of omeprazole and esomeprazole, concomitant administration with esomeprazole and atazanavir is not recommended (see section 4.4) and concomitant administration with esomeprazole and nelfinavir is contraindicated (see section 4.3).</p><p>For saquinavir (with concomitant ritonavir), increased serum levels (80-100%) have been reported during concomitant omeprazole treatment (40 mg qd). Treatment with omeprazole 20 mg qd had no effect on the exposure of darunavir (with concomitant ritonavir) and amprenavir (with concomitant ritonavir). Treatment with esomeprazole 20 mg qd had no effect on the exposure of amprenavir (with and without concomitant ritonavir). Treatment with omeprazole 40 mg qd had no effect on the exposure of lopinavir (with concomitant ritonavir).</p><p><em><u>Methotrexate</u></em></p><p>When given together with PPIs, methotrexate levels have been reported to increase in some patients. In high-dose methotrexate administration a temporary withdrawal of esomeprazole may need to be considered.</p><p><em><u>Tacrolimus</u></em></p><p>Concomitant administration of esomeprazole has been reported to increase the serum levels of tacrolimus. A reinforced monitoring of tacrolimus concentrations as well as renal function (creatinine clearance) should be performed, and dosage of tacrolimus adjusted if needed.</p><p><em><u>Medicinal products with pH dependent absorption</u></em></p><p>Gastric acid suppression during treatment with esomeprazole and other PPIs might decrease or increase the absorption of medicinal products with a gastric pH dependent absorption. As with other medicinal products that decrease intragastric acidity, the absorption of medicinal products such as ketoconazole, itraconazole and erlotinib can decrease and the absorption of digoxin can increase during treatment with esomeprazole. Concomitant treatment with omeprazole (20 mg daily) and digoxin in healthy subjects increased the bioavailability of digoxin by 10% (up to 30% in two out of ten subjects). Digoxin toxicity has been rarely reported. However, caution should be exercised when esomeprazole is given at high doses in elderly patients. Therapeutic drug monitoring of digoxin should then be reinforced.</p><p><em><u>Medicinal products metabolized by CYP2C19</u></em></p><p>Esomeprazole inhibits CYP2C19, the major esomeprazole-metabolizing enzyme. Thus, when esomeprazole is combined with drugs metabolized by CYP2C19, such as diazepam, citalopram, imipramine, clomipramine, phenytoin etc., the plasma concentrations of these drugs may be increased and a dose reduction could be needed. This should be considered especially when prescribing esomeprazole for on-demand therapy.</p><p><em><u>Diazepam</u></em></p><p>Concomitant administration of 30 mg esomeprazole resulted in a 45% decrease in clearance of the CYP2C19 substrate diazepam.</p><p><em><u>Phenytoin</u></em></p><p>Concomitant administration of 40 mg esomeprazole resulted in a 13% increase in trough plasma levels of phenytoin in epileptic patients. It is recommended to monitor the plasma concentrations of phenytoin when treatment with esomeprazole is introduced or withdrawn.</p><p><em><u>Voriconazole</u></em></p><p>Omeprazole (40 mg once daily) increased voriconazole (a CYP2C19 substrate) C<sub>max&nbsp;</sub>and AUC<sub> </sub>&nbsp;by 15% and 41%, respectively.</p><p><em><u>Cilostazol</u></em></p><p>Omeprazole as well as esomeprazole act as inhibitors of CYP2C19. Omeprazole, given in doses of 40 mg to healthy subjects in a cross-over study, increased C<sub>max</sub>&nbsp;and AUC for cilostazol by 18% and 26% respectively, and one of its active metabolites by 29% and 69% respectively.</p><p><em><u>Cisapride</u></em></p><p>In healthy volunteers, concomitant administration of 40 mg esomeprazole resulted in a 32% increase in area under the plasma concentration-time curve (AUC) and a 31% prolongation of elimination half-life (t<sub>1/2</sub>) but no significant increase in peak plasma levels of cisapride. The slightly prolonged QTc interval observed after administration of cisapride alone, was not further prolonged when cisapride was given in combination with esomeprazole (see also section 4.4).</p><p><em><u>Warfarin</u></em></p><p>Concomitant administration of 40 mg esomeprazole to warfarin-treated patients in a clinical trial showed that coagulation times were within the accepted range. However, post-marketing, a few isolated cases of elevated INR of clinical significance have been reported during concomitant treatment. Monitoring is recommended when initiating and ending concomitant esomeprazole treatment during treatment with warfarin or other coumarine derivatives.</p><p><em><u>Clopidogrel</u></em></p><p>Results from studies in healthy subjects have shown a pharmacokinetic (PK)/ pharmacodynamics (PD) interaction between clopidogrel (300 mg loading dose/75 mg daily maintenance dose) and esomeprazole (40 mg p.o.daily) resulting in decreased exposure to the active metabolite of clopidogrel by an average of 40% and resulting in decreased maximum inhibition of (ADP induced) platelet aggregation by an average of 14%.</p><p>When clopidogrel was given together with a fixed dose combination of esomeprazole 20 mg + ASA 81 mg compared to clopidogrel alone in a study in healthy subjects there was a decreased exposure by almost 40% of the active metabolite of clopidogrel. However, the maximum levels of inhibition of (ADP induced) platelet aggregation in these subjects were the same in the clopidogrel and the clopidogrel + the combined (esomeprazole + ASA) product groups.</p><p>Inconsistent data on the clinical implications of a PK/PD interaction of esomeprazole in terms of major cardiovascular events have been reported from both observational and clinical studies. As a precaution concomitant use of clopidogrel should be discouraged.</p><p><em><u>Investigated medicinal products with no clinically relevant interaction</u></em></p><p><em>Amoxicillin and quinidine</em></p><p>Esomeprazole has been shown to have no clinically relevant effects on the pharmacokinetics of amoxicillin or quinidine.</p><p><em>Naproxen or rofecoxib</em></p><p>Studies evaluating concomitant administration of esomeprazole and either naproxen or rofecoxib did not identify any clinically relevant pharmacokinetic interactions during short-term studies.</p><p><u>Effects of other medicinal products on the pharmacokinetics of esomeprazole</u></p><p><em><u>Medicinal products which inhibit CYP2C19 and/or CYP3A4</u></em></p><p>Esomeprazole is metabolized by CYP2C19 and CYP3A4. Concomitant administration of esomeprazole and a CYP3A4 inhibitor, clarithromycin (500 mg b.i.d.), resulted in a doubling of the exposure (AUC) to esomeprazole. Concomitant administration of esomeprazole and a combined inhibitor of CYP2C19 and CYP3A4 may result in more than doubling of the esomeprazole exposure. The CYP2C19 and CYP3A4 inhibitor voriconazole increased omeprazole AUC<sub> &nbsp;</sub>by 280%. A dose adjustment of esomeprazole is not regularly required in either of these situations. However, dose adjustment should be considered in patients with severe hepatic impairment and if long-term treatment is indicated.</p><p><em><u>Medicinal products which induce CYP2C19 and/or CYP3A4</u></em></p><p>Drugs known to induce CYP2C19 or CYP3A4 or both (such as rifampicin and St. John&#39;s wort) may lead to decreased esomeprazole serum levels by increasing the esomeprazole metabolism.</p><p><em><u>Paediatric population</u></em></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;<u>Pregnancy</u></p><p>Clinical data on exposed pregnancies with Esoma are insufficient. With the racemic mixture omeprazole data on a larger number of exposed pregnancies stemmed from epidemiological studies indicate no malformative nor foetotoxic effects. Animal studies with esomeprazole do not indicate direct or indirect harmful effects with respect to embryonal/foetal development. Animal studies with the racemic mixture do not indicate direct or indirect harmful effects with respect to pregnancy, parturition or postnatal development. Caution should be exercised when prescribing to pregnant women.</p><p>A moderate amount of data on pregnant women (between 300-1000 pregnancy outcomes) indicates no malformative or foeto/neonatal toxicity of esomeprazole.</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3).</p><p><u>Breast-feeding</u></p><p>It is not known whether esomeprazole is excreted in human breast milk. There is insufficient information on the effects of esomeprazole in newborns/infants. Esomeprazole should not be used during breast-feeding.</p><p><u>Fertility</u></p><p>Animal studies with the racemic mixture omeprazole, given by oral administration do not indicate effects with respect to fertility.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Esomeprazole has minor influence on the ability to drive or use machines. Adverse reactions such as dizziness (uncommon) and blurred vision (rare) has been reported (see section 4.8). If affected patients should not drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>Headache, abdominal pain, diarrhoea and nausea are among those adverse reactions that have been most commonly reported in clinical trials (and also from post-marketing use). In addition, the safety profile is similar for different formulations, treatment indications, age groups and patient populations. No dose-related adverse reactions have been identified.</p><p><u>Tabulated list of adverse reactions</u></p><p>The following adverse drug reactions have been identified or suspected in the clinical trials programme for esomeprazole and post-marketing. None was found to be dose-related. The reactions are classified according to frequency very common &ge;1/10; common &ge;1/100 to &lt;1/10; uncommon &ge;1/1,000 to &lt;1/100; rare &ge;1/10,000 to &lt;1/1,000; very rare &lt;1/10,000; not known (cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Undesirable Effect</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Leukopenia, thrombocytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Agranulocytosis, pancytopenia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions e.g. fever, angioedema and anaphylactic reaction/shock</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Peripheral oedema</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Hypomagnesaemia (see section 4.4); severe hypomagnesaemia can correlate with hypocalcaemia. Hypomagnesaemia may also be associated with hypokalaemia.</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Insomnia</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Agitation, confusion, depression</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Aggression, hallucinations</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Headache</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dizziness, paraesthesia, somnolence</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Taste disturbance</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Blurred vision</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Bronchospasm</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Abdominal pain, constipation, diarrhoea, flatulence, nausea/vomiting</p><p>fundic gland polyps (benign)</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Stomatitis, gastrointestinal candidiasis</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Microscopic colitis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Increased liver enzymes</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hepatitis with or without jaundice</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hepatic failure, encephalopathy in patients with pre-existing liver disease</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dermatitis, pruritus, rash, urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Alopecia, photosensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Subacute cutaneous lupus erythematosus (see section 4.4)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Fracture of the hip, wrist or spine (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Arthralgia, myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Muscular weakness</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Interstitial nephritis; in some patients renal failure has been reported concomitantly.</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Gynaecomastia</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Malaise, increased sweating</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>To report any side effects</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; National Pharmacovigilance and Drug Safety Center (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o To call the executive management of vigilance and crisis management: +966-11-2038222 ext.: 2353 &ndash; 2356 &ndash; 2317 &ndash; 2354 &ndash; 2334 &ndash; 2340</p><p>o Toll-free: 8002490000</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is very limited experience to date with deliberate overdose. The symptoms described in connection with 280 mg were gastrointestinal symptoms and weakness. Single doses of 80 mg esomeprazole were uneventful. No specific antidote is known. Esomeprazole is extensively plasma protein bound and is therefore not readily dialyzable. As in any case of overdose, treatment should be symptomatic and general supportive measures should be utilized.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs for acid-related disorders proton pump inhibitors</p><p>ATC Code: A02B C05</p><p>Esomeprazole is the&nbsp;<em>S</em>-isomer of omeprazole and reduces gastric acid secretion through a specific targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. Both the&nbsp;<em>R</em>- and&nbsp;<em>S</em>-isomer of omeprazole have similar pharmacodynamics activity.</p><p><u>Mechanism of action</u></p><p>Esomeprazole is a weak base and is concentrated and converted to the active form in the highly acidic environment of the secretory canaliculi of the parietal cell, where it inhibits the enzyme H<sup>+</sup>K<sup>+</sup>-ATPase &ndash; the acid pump and inhibits both basal and stimulated acid secretion.</p><p><u>Pharmacodynamic effects</u></p><p>After oral dosing with esomeprazole 20 mg and 40 mg the onset of effect occurs within one hour. After repeated administration with 20 mg esomeprazole once daily for five days, mean peak acid output after pentagastrin stimulation is decreased 90% when measured 6&ndash;7 hours after dosing on day five.</p><p>After five days of oral dosing with 20 mg and 40 mg of esomeprazole, intragastric pH above 4 was maintained for a mean time of 13 hours and 17 hours, respectively over 24 hours in symptomatic GERD patients. The proportion of patients maintaining an intragastric pH above 4 for at least 8, 12 and 16 hours respectively were for esomeprazole 20 mg 76%, 54% and 24%. Corresponding proportions for esomeprazole 40 mg were 97%, 92% and 56%.</p><p>Using AUC as a surrogate parameter for plasma concentration, a relationship between inhibition of acid secretion and exposure has been shown.</p><p>Healing of reflux esophagitis with esomeprazole 40 mg occurs in approximately 78% of patients after four weeks, and in 93% after eight weeks.</p><p>One week&rsquo;s treatment with esomeprazole 20 mg b.i.d. and appropriate antibiotics, results in successful eradication of&nbsp;<em>H. pylori</em>&nbsp;in approximately 90% of patients.</p><p>After eradication treatment for one week, there is no need for subsequent monotherapy with antisecretory drugs for effective ulcer healing and symptom resolution in uncomplicated duodenal ulcers.</p><p>In a randomized, double blind, placebo-controlled clinical study, patients with endoscopically confirmed peptic ulcer bleeding characterized as Forrest Ia, Ib, IIa or IIb (9%, 43%, 38% and 10% respectively) were randomized to receive Esoma solution for infusion (n=375) or placebo (n=389). Following endoscopic haemostasis, patients received either 80 mg esomeprazole as an intravenous infusion over 30 minutes followed by a continuous infusion of 8 mg per hour or placebo for 72 hours. After the initial 72-hour period, all patients received open label 40 mg oral Esoma for 27 days for acid suppression. The occurrence of rebleeding within 3 days was 5.9% in the Esoma treated group compared to 10.3% for the placebo group. At 30 days post-treatment, the occurrence of rebleeding in the Esoma treated versus the placebo treated group was 7.7% vs 13.6%.</p><p>During treatment with antisecretory medicinal products, serum gastrin increases in response to the decreased acid secretion. Also CgA increases due to decreased gastric acidity. The increased CgA level may interfere with investigations&nbsp;for neuroendocrine tumours. Available published evidence suggests that proton pump inhibitors should be discontinued between 5 days and 2 weeks prior to CgA measurements. This is to allow CgA levels that might be spuriously elevated following PPI treatment to return to reference range.</p><p>An increased number of ECL cells possibly related to the increased serum gastrin levels, have been observed in both children and adults during long-term treatment with esomeprazole. The findings are considered to be of no clinical significance.</p><p>During long-term treatment with antisecretory drugs, gastric glandular cysts have been reported to occur at a somewhat increased frequency. These changes are a physiological consequence of pronounced inhibition of acid secretion, are benign and appear to be reversible.</p><p>Decreased gastric acidity due to any means including proton pump inhibitors, increases gastric counts of bacteria normally present in the gastrointestinal tract. Treatment with proton pump inhibitors may lead to slightly increased risk of gastrointestinal infections such as&nbsp;<em>Salmonella&nbsp;</em>and&nbsp;<em>Campylobacter</em>&nbsp;and, in hospitalized patients, possibly also&nbsp;<em>Clostridium difficile</em>.</p><p><u>Clinical efficacy</u></p><p>In two studies with ranitidine as an active comparator, Esoma showed better effect in healing of gastric ulcers in patients using NSAIDs, including COX-2 selective NSAIDs.</p><p>In two studies with placebo as comparator, Esoma showed better effect in the prevention of gastric and duodenal ulcers in patients using NSAIDs (aged &gt;60 and/or with previous ulcer), including COX-2 selective NSAIDs.</p><p><u>Paediatric population</u></p><p>In a study in paediatric GERD patients (&lt;1 to 17 years of age) receiving long-term PPI treatment, 61% of the children developed minor degrees of ECL cell hyperplasia with no known clinical significance and with no development of atrophic gastritis or carcinoid tumours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Esomeprazole is acid labile and is administered orally as enteric-coated granules.&nbsp;<em>In vivo</em>&nbsp;conversion to the&nbsp;<em>R</em>-isomer is negligible. Absorption of esomeprazole is rapid, with peak plasma levels occurring approximately 1-2 hours after dose. The absolute bioavailability is 64% after a single dose of 40 mg and increases to 89% after repeated once daily administration. For 20 mg esomeprazole the corresponding values are 50% and 68%, respectively.</p><p><strong>Food intake both delays and decreases the absorption of esomeprazole although this has no significant influence on the effect of esomeprazole on intragastric acidity.</strong></p><p><u>Distribution</u></p><p>The apparent volume of distribution at steady state in healthy subjects is approximately 0.22 l/kg body weight. Esomeprazole is 97% plasma protein bound.</p><p><u>Biotransformation</u></p><p>Esomeprazole is completely metabolized by the cytochrome P450 system (CYP). The major part of the metabolism of esomeprazole is dependent on the polymorphic CYP2C19, responsible for the formation of the hydroxy- and desmethyl metabolites of esomeprazole. The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of esomeprazole sulphone, the main metabolite in plasma.</p><p><u>Elimination</u></p><p>The parameters below reflect mainly the pharmacokinetics in individuals with a functional CYP2C19 enzyme, extensive metabolizers.</p><p>Total plasma clearance is about 17 l/h after a single dose and about 9 l/h after repeated administration. The plasma elimination half-life is about 1.3 hours after repeated once daily dosing. Esomeprazole is completely eliminated from plasma between doses with no tendency for accumulation during once-daily administration.</p><p>The major metabolites of esomeprazole have no effect on gastric acid secretion. Almost 80% of an oral dose of esomeprazole is excreted as metabolites in the urine, the remainder in the faeces. Less than 1% of the parent drug is found in urine.</p><p><u>Linearity/non-linearity</u></p><p>The pharmacokinetics of esomeprazole has been studied in doses up to 40 mg b.i.d. The area under the plasma concentration-time curve increases with repeated administration of esomeprazole. This increase is dose-dependent and results in a more than dose proportional increase in AUC after repeated administration. This time- and dose-dependency is due to a decrease of first pass metabolism and systemic clearance probably caused by an inhibition of the CYP2C19 enzyme by esomeprazole and/or its sulphone metabolite.</p><p><u>Special patient populations</u></p><p><em><u>Poor metabolizers</u></em></p><p>Approximately 2.9 &plusmn;1.5% of the population lack a functional CYP2C19 enzyme and are called poor metabolizers. In these individuals the metabolism of esomeprazole is probably mainly catalyzed by CYP3A4. After repeated once daily administration of 40 mg esomeprazole, the mean area under the plasma concentration-time curve was approximately 100% higher in poor metabolizers than in subjects having a functional CYP2C19 enzyme (extensive metabolizers). Mean peak plasma concentrations were increased by about 60%. These findings have no implications for the posology of esomeprazole.</p><p><em><u>Gender</u></em></p><p>Following a single dose of 40 mg esomeprazole the mean area under the plasma concentration-time curve is approximately 30% higher in females than in males. No gender difference is seen after repeated once daily administration. These findings have no implications for the posology of esomeprazole.</p><p><em><u>Hepatic impairment</u></em></p><p>The metabolism of esomeprazole in patients with mild to moderate liver dysfunction may be impaired. The metabolic rate is decreased in patients with severe liver dysfunction resulting in a doubling of the area under the plasma concentration-time curve of esomeprazole. Therefore, a maximum of 20 mg should not be exceeded in patients with severe dysfunction. Esomeprazole or its major metabolites do not show any tendency to accumulate with once daily dosing.</p><p><em><u>Renal impairment</u></em></p><p>No studies have been performed in patients with decreased renal function. Since the kidney is responsible for the excretion of the metabolites of esomeprazole but not for the elimination of the parent compound, the metabolism of esomeprazole is not expected to be changed in patients with impaired renal function.</p><p><em><u>Elderly</u></em></p><p>The metabolism of esomeprazole is not significantly changed in elderly subjects (71-80 years of age).</p><p><em><u>Paediatric population</u></em></p><p><em>Adolescents 12-18 years:</em></p><p>Following repeated dose administration of 20 mg and 40 mg esomeprazole, the total exposure (AUC) and the time to reach maximum plasma concentration (t<sub>max</sub>) in 12 to 18 year-olds was similar to that in adults for both esomeprazole doses.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows:</p><p>Carcinogenicity studies in the rat with the racemic mixture have shown gastric ECL-cell hyperplasia and carcinoids. These gastric effects in the rat are the result of sustained, pronounced hypergastrinaemia secondary to reduced production of gastric acid and are observed after long-term treatment in the rat with inhibitors of gastric acid secretion.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hard gelatin capsule shell (size 4 for ESOMA 20 mg &amp; size 3 for ESOMA 40 mg).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30 &deg;C</p><p>Store in the original pack to protect from light &amp; moisture</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>ESOMA 20 mg:</strong>&nbsp;28 Capsules, 4 strips (7 Capsules/Strip)&nbsp;&nbsp; &amp; 14 Capsules, 2 strips (7 Capsules/Strip)&nbsp;&nbsp;</p><p><strong>ESOMA 40 mg:</strong> 28 Capsules, 4 strips (7 Capsules /Strip)&nbsp;&nbsp;&amp; 14 Capsules, 2 strips (7 Capsules /Strip)&nbsp;&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)
P.O. Box 442, Riyadh 11411
Fax: +966 11 265 0505
Email: contact@riyadhpharma.com
For any information about this medicinal product, please contact the local representative of marketing authorisation holder:
Saudi Arabia
Marketing department
Riyadh
Tel: +966 11 265 0111
Email: marketing@riyadhpharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                03/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>